What is the appropriate diagnostic workup for a patient suspected of systemic lupus erythematosus?

Diagnostic Workup of Systemic Lupus Erythematosus

Initial Screening

Begin with ANA testing using a 1:160 dilution cutoff as the entry criterion—if positive, proceed with comprehensive autoantibody panel and multi-organ system evaluation to apply the EULAR/ACR 2019 classification criteria, which are 96.1% sensitive and 93.4% specific for SLE. 1, 2, 3

• Use 1:160 dilution specifically in unselected populations to minimize false positives 1, 2
• Only order ANA testing when patients present with unexplained involvement of two or more organ systems 4
• An ANA titer less than 1:40 generally rules out SLE, though rare ANA-negative disease exists in patients with persistent multisystem involvement 4

Confirmatory Autoantibody Testing

When ANA is positive, obtain the following immunologic markers:

• Anti-dsDNA antibodies using a double-screening strategy: perform last-generation solid phase assay first, then confirm positive results with Crithidia luciliae immunofluorescence test 1, 2
• Complement levels (C3 and C4): Low complement combined with positive anti-dsDNA strongly supports active SLE 1, 2
• Anti-Ro/SSA and anti-La/SSB antibodies, particularly in women of childbearing age due to associations with neonatal lupus and congenital heart block 2, 5
• Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2-glycoprotein I IgG/IgM) due to associations with thrombosis, seizures, cognitive dysfunction, and pregnancy complications 6, 2

Essential Baseline Laboratory Tests

Order the following at initial evaluation:

• Complete blood count with differential to detect cytopenias (anemia, thrombocytopenia, leukopenia, lymphopenia)—all associated with disease activity and worse prognosis 6, 2, 5
• Serum creatinine (or estimated GFR) and serum albumin for renal function assessment 6, 2
• Urinalysis with microscopy and urine protein-to-creatinine ratio to detect lupus nephritis 6, 2
• Erythrocyte sedimentation rate (ESR) for inflammatory activity 6, 2
• C-reactive protein (CRP): Note that SLE patients rarely have elevated CRP—values >50 mg/L strongly suggest superimposed bacterial infection rather than lupus activity alone 2, 5

Clinical System-by-System Evaluation

Mucocutaneous Assessment

• Document and characterize skin lesions as LE-specific (acute, subacute, or chronic cutaneous lupus), LE non-specific, LE mimickers, or drug-related 6
• Skin biopsy is mandatory when cutaneous lesions are present for histological confirmation 1, 2, 5
• Use the Cutaneous Lupus Disease Area and Severity Index (CLASI) to quantify disease activity and damage 6, 5

Renal Assessment

• Patients with persistently abnormal urinalysis or raised serum creatinine require urine protein-to-creatinine ratio (or 24-hour proteinuria), urine microscopy, and renal ultrasound 6
• Perform renal biopsy when lupus nephritis is suspected to confirm diagnosis, assess disease activity versus chronicity, and guide immunosuppressive therapy 1, 2

Neuropsychiatric Assessment

• Screen systematically for seizures, psychosis, acute confusional state, cognitive impairment (attention, concentration, word-finding, memory difficulties), headache, mood disorders, paresthesiae, numbness, and weakness 6, 2
• If cognitive impairment is suspected (problems with multitasking, household tasks, or memory), perform detailed neuropsychological assessment 6
• Obtain cerebrospinal fluid examination (including PCR for HSV and JC virus) when fever or signs of CNS infection are present 6
• EEG studies help diagnose underlying seizure disorder 6
• MRI with T1/T2-weighted imaging, fluid-attenuating inversion recovery sequence, diffusion-weighted imaging, and gadolinium-enhanced T1-weighted sequence is the imaging technique of choice (57% average sensitivity in active NPSLE) 6

Musculoskeletal Assessment

• Assess for active arthritis and serositis 2
• Joint pain is present in 60% of patients at initial presentation 7

Hematologic Assessment

• Evaluate for cytopenias, which occur in 22% of patients and correlate with disease activity 2, 7

Ophthalmologic Assessment

• Baseline eye examination is recommended for patients who will be treated with glucocorticoids or antimalarials 6

Diagnostic Confirmation

Apply the EULAR/ACR 2019 classification criteria as the standard for diagnosis, which requires positive ANA as an entry criterion, involvement of at least two organ systems, and sufficient weighted criteria points. 1, 2, 3

Common Pitfalls to Avoid

• Do not rely solely on ANA testing, as it can be positive in other conditions and has low predictive value in primary care populations without typical multisystem symptoms 2, 4
• Recognize that most common initial presentations are nonspecific: fever (71%), joint pain (60%), and alopecia (28%) 7
• Remember that headache, mood disorders, anxiety, and mild cognitive dysfunction are common but do not usually reflect overt CNS lupus activity 6
• If anti-dsDNA and complement levels are initially negative or normal, repeat them at follow-up visits as they may become positive with disease activity 1, 2

Post-Diagnosis Monitoring Strategy

• Use validated activity indices (SLEDAI, BILAG, or SLE-DAS) to monitor lupus activity and detect flares 1
• Monitor every 6-12 months with CBC, ESR, CRP, serum albumin, creatinine, urinalysis, anti-dsDNA, C3, and C4 levels 1, 2
• For established nephropathy, check protein-to-creatinine ratio, immunological tests (C3, C4, anti-dsDNA), urine microscopy, and blood pressure at least every 3 months for the first 2-3 years 6
• Patients with anti-C1q antibodies have nearly 100% prevalence during active lupus nephritis, and absence makes flare-up doubtful 1
• Persistent anti-dsDNA antibodies and hypocomplementemia after treatment indicate high risk for renal relapse 1